Document is current

Article History

Received: 3 February 2025

Revised: 2 March 2026

Accepted: 9 April 2026

First Online: 27 April 2026

Competing interests

: JWN reports grants from Genetech/Roche, grants from Merck, grants from Boehringer Ingelheim, grants from Exelixis, grants from Nektar Therapeutics, grants from Takeda Pharmaceuticals, grants from Adaptimmune, grants from GSK, grants from Janssen, grants from AbbVie, other from CME Matters, other from Clinical Care Options, other from Research to Practice, other from Medscape, other from Biomedical Learning Institute, other from MLI Peerview, other from Prime Oncology, other from Projects in Knowledge, other from Rockpointe, other from MJH Life Science, other from AstraZeneca, other from Genetech/Roche, other from Exelixis, other from Jounce Therapeutics, other from Takeda Pharmaceuticals, other from Eli Lilly and Company, other from Calithera BIosciences, other from Amgen, other from Iovance Biotherapeutics, other from Blueprint Pharmaceuticals, other from Regeneron Pharmaceuticals, other from Natera, outside the submitted work. Dr. Wakelee reports grants from ACEA Biosciences, grants from Arrys Therapeutics, grants from BMS, grants from Celgene, grants from Clovis Oncology, grants from Exelixis, grants from Genetech/Roche, grants from Gilead, grants from Merck, grants from Novartis, grants from Pharmacyclics, grants from Sea Gen, grants from Xcovery, other from AstraZeneca, other from Xcovery, other from Janssen, other from Daiichi Sankyo, other from Blueprint, other from Mirati, other from Helsinn, other from Merch - Not compensated, other from Genetech/Roche - Not compensated, other from IASLC, other from ECOG-ACRIN, outside the submitted work. All remaining authors report no other disclosures.